December 2017 - Cancer Currents Blog
- Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma
The FDA has granted accelerated approval to acalabrutinib (Calquence®) for the treatment of adults with mantle cell lymphoma whose cancer has progressed after receiving at least one prior therapy.
- With Advances in Cancer Immunotherapy, Scientists Discuss Need to Develop New Mouse Models
A recent NCI symposium focused on developing new and better mouse models for testing treatments that harness the immune system against cancer.
- FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer
FDA has approved alectinib (Alecensa) as a first-line treatment option for patients with advanced non-small cell lung cancer that is ALK positive. Alectinib is the third ALK inhibitor to be approved in this setting.
- Fat Cells May Hinder Effectiveness of Chemotherapy
Researchers have shown that fat cells can absorb two commonly used chemotherapy drugs and break them down chemically into a less toxic form, potentially reducing the drugs’ effectiveness.
- Expanding Cancer Clinical Trial Access for Patients with HIV
People with HIV are often excluded from clinical trials for safety reasons. Preliminary results from an NCI-sponsored study of an immunotherapy drug show that people with HIV can safely participate in clinical trials.